Adam M Brufsky

List of Publications by Year
in descending order

425 papers	34,275 citations	7069 78 h-index	4101 175 g-index
442 all docs	442 docs citations	442 times ranked	38529 citing authors

#	Article	IF	Citations
1	Personalising therapy for early-stage oestrogen receptor-positive breast cancer in older women. The Lancet Healthy Longevity, 2022, 3, e54-e66.	2.0	9
2	Machine Learning to Discern Interactive Clusters of Risk Factors for Late Recurrence of Metastatic Breast Cancer. Cancers, 2022, 14, 253.	1.7	3
3	Genetic Polymorphisms and Correlation with Treatment-Induced Cardiotoxicity and Prognosis in Patients with Breast Cancer. Clinical Cancer Research, 2022, 28, 1854-1862.	3.2	5
4	Behavioral and health outcomes from the NRG Oncology/NSABP B-36 trial comparing two different adjuvant therapy regimens for early-stage node-negative breast cancer. Breast Cancer Research and Treatment, 2022, 192, 153-161.	1.1	1
5	The importance of accessory protein variants in the pathogenicity of SARS-CoV-2. Archives of Biochemistry and Biophysics, 2022, 717, 109124.	1.4	20
6	Breast cancer mortality as a function of age. Aging, 2022, 14, .	1.4	2
7	Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). Breast Cancer Research and Treatment, 2022, 193, 555-564.	1.1	5
8	Abstract OT2-17-01: Randomized, multicenter, international phase 3 ARTEST study to evaluate the efficacy and safety of enobosarm versus active control for the treatment of AR+ ER+ HER2- metastatic breast cancer in patients who progressed on a nonsteroidal aromatase inhibitor, fulvestrant and CDK 4/6 inhibitor. Cancer Research, 2022, 82, OT2-17-01-OT2-17-01.	0.4	1
9	Abstract P5-16-01: Assessment of health-related quality of life by clinical response from the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-16-01-P5-16-01.	0.4	0
10	Real-World Treatment Patterns and Clinical Effectiveness of Palbociclib Plus an Aromatase Inhibitor as First-Line Therapy in Advanced/Metastatic Breast Cancer: Analysis from the US Syapse Learning Health Network. Current Oncology, 2022, 29, 1047-1061.	0.9	4
11	Abstract OT1-14-01: Zanidatamab in combination with ALX148 in advanced human epidermal growth factor receptor 2 (HER2)-expressing cancers, including breast cancer: A phase 1b/2, multicenter, open-label, dose-finding and cohort-expansion study (ZWI-ZW25-204). Cancer Research, 2022, 82, OT1-14-01-OT1-14-01.	0.4	2
12	Abstract PD2-03: Association between co-existing genomic alterations and abemaciclib benefit in patients with metastatic hormone receptor-positive breast cancer with ESR1 mutations following disease progression on prior endocrine therapy plus palbociclib or ribociclib. Cancer Research, 2022, 82, PD2-03-PD2-03.	0.4	0
13	Abstract P2-11-19: Estimating the long-term risk of recurrence in patients receiving HER2-targeted agents in HER2+ early-stage breast cancer (ESBC). Cancer Research, 2022, 82, P2-11-19-P2-11-19.	0.4	0
14	Abstract P5-16-15: Post-progression therapy outcomes in patients (pts) from the phase 3 ASCENT study of sacituzumab govitecan (SG) in metastatic triple-negative breast cancer (mTNBC). Cancer Research, 2022, 82, P5-16-15-P5-16-15.	0.4	2
15	Abstract P1-18-20: Real-world effectiveness of palbociclib plus letrozole vs letrozole alone for metastatic breast cancer with lung/liver metastases: Flatiron database analysis. Cancer Research, 2022, 82, P1-18-20-P1-18-20.	0.4	0
16	Abstract P5-18-02: Final findings from the CONTROL trial of diarrheal prophylaxis or neratinib dose escalation on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer. Cancer Research, 2022, 82, P5-18-02-P5-18-02.	0.4	1
17	Abstract PD15-05: Assessment of estrogen receptor (ESR1) mRNA expression for prediction of extended aromatase inhibitor benefit in HR-positive breast cancer using NRG Oncology/NSABP B-42. Cancer Research, 2022, 82, PD15-05-PD15-05.	0.4	0
18	Abstract GS4-10: Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastatic breast cancer and neratinib + trastuzumab for triple-negative disease: Latest updates from the SUMMIT trial. Cancer Research, 2022, 82, GS4-10-GS4-10.	0.4	6

#	Article	IF	Citations
19	Doxorubicin induced tongue hyperpigmentation. Current Problems in Cancer Case Reports, 2022, 5, 100147.	0.1	1
20	An issue of concern: unique truncated ORF8 protein variants of SARS-CoV-2. PeerJ, 2022, 10, e13136.	0.9	7
21	Clinical-pathologic characteristics and response to neoadjuvant chemotherapy in triple-negative low Ki-67 proliferation (TNLP) breast cancers. Npj Breast Cancer, 2022, 8, 51.	2.3	9
22	Would New SARS-CoV-2 Variants Change the War against COVID-19?. Epidemiologia, 2022, 3, 229-237.	1.1	3
23	Analysis of patients without and with an initial triple-negative breast cancer diagnosis in the phase 3 randomized ASCENT study of sacituzumab govitecan in metastatic triple-negative breast cancer. Breast Cancer Research and Treatment, 2022, 195, 127-139.	1.1	15
24	Real-World Treatment Patterns and Outcomes of Palbociclib Plus an Aromatase Inhibitor for Metastatic Breast Cancer: Flatiron Database Analysis. Clinical Breast Cancer, 2022, 22, 601-610.	1.1	10
25	Investigation of a genomic signature for transcription factor MAF gene amplification and lack of bisphosphonate benefit in early breast cancer.. Journal of Clinical Oncology, 2022, 40, 559-559.	0.8	0
26	Sacituzumab govitecan (SG) versus treatment of physicianâ€™s choice (TPC) in patients (pts) with previously treated, metastatic triple-negative breast cancer (mTNBC): Final results from the phase 3 ASCENT study.. Journal of Clinical Oncology, 2022, 40, 1071-1071.	0.8	7
27	Effect of socioeconomic status as measured by Neighborhood Deprivation Index on survival in metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, 1013-1013.	0.8	0
28	Whole transcriptome analysis of tumors with discordant oncotype and MammaPrint results in the FLEX trial.. Journal of Clinical Oncology, 2022, 40, 556-556.	0.8	0
29	FLEX, the 30,000 breast cancer transcriptome project: A platform for early breast cancer research using full-genome arrays paired with clinical data.. Journal of Clinical Oncology, 2022, 40, TPS612-TPS612.	0.8	0
30	Neratinib plus fulvestrant plus trastzuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial.. Journal of Clinical Oncology, 2022, 40, 1028-1028.	0.8	9
31	Clinical implications for patients with discordant oncotype and MammaPrint results.. Journal of Clinical Oncology, 2022, 40, 560-560.	0.8	0
32	Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy.. Journal of Clinical Oncology, 2022, 40, TPS1121-TPS1121.	0.8	2
33	Defining transcriptomic profiles of early-stage mucinous breast cancers: A FLEX sub study.. Journal of Clinical Oncology, 2022, 40, 3134-3134.	0.8	0
34	Adherence to EndoPredict test scores for extended endocrine therapy management in the prospective EndoPredict Extended Endocrine Trial (EXET).. Journal of Clinical Oncology, 2022, 40, 537-537.	0.8	1
35	The structural basis of accelerated host cell entry by SARSâ€CoVâ€2â€. FEBS Journal, 2021, 288, 5010-5020.	2.2	129
36	Impaired glucose metabolism in patients with diabetes, prediabetes, and obesity is associated with severe COVIDâ€19. Journal of Medical Virology, 2021, 93, 409-415.	2.5	141

#	Article	IF	Citations
37	Magee Equationsâ„¢ and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study. Modern Pathology, 2021, 34, 77-84.	2.9	14
38	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. Journal of the National Cancer Institute, 2021, 113, 390-399.	3.0	62
39	Physical activity, cardiorespiratory fitness, and cognitive function in postmenopausal women with breast cancer. Supportive Care in Cancer, 2021, 29, 3743-3752.	1.0	7
40	Questions concerning the proximal origin of SARSâ€CoVâ€2. Journal of Medical Virology, 2021, 93, 1204-1206.	2.5	56
41	Potential interventions for SARSâ€CoVâ€2 infections: Zinc showing promise. Journal of Medical Virology, 2021, 93, 1201-1203.	2.5	17
42	Statins and endocrine resistance in breast cancer. , 2021, 4, 356-364.		7
43	Reply to T. J. A. Dekker, D.-C. Mo et al, and A. Seidman et al. Journal of Clinical Oncology, 2021, 39, 254-255.	0.8	1
44	Abstract PS1-10: Outcomes after sentinel lymph node biopsy and radiation therapy in women over 70 years old with ER+, HER2-, clinically node negative breast cancer. , 2021, , .		0
45	Baseline characteristics and first-line treatment patterns in patients with HER2-positive metastatic breast cancer in the SystHERs registry. Breast Cancer Research and Treatment, 2021, 188, 179-190.	1.1	5
46	Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2â^' metastatic breast cancer in US real-world clinical practice. Breast Cancer Research, 2021, 23, 37.	2.2	65
47	Approaching Neoadjuvant Therapy in the Management of Early-Stage Breast Cancer. Breast Cancer: Targets and Therapy, 2021, Volume 13, 199-211.	1.0	15
48	Urgent Need for Field Surveys of Coronaviruses in Southeast Asia to Understand the SARS-CoV-2 Phylogeny and Risk Assessment for Future Outbreaks. Biomolecules, 2021, 11, 398.	1.8	3
49	Considerations of the effects of commonly investigated drugs for COVID-19 in the cholesterol synthesis pathway. Expert Opinion on Pharmacotherapy, 2021, 22, 1-6.	0.9	2
50	Voltage-Gated Calcium Channel Antibody-Induced Oropharyngeal Dysphagia Presenting as a Paraneoplastic Neurological Complication in Breast Cancer. Cureus, 2021, 13, e13677.	0.2	1
51	Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. New England Journal of Medicine, 2021, 384, 1529-1541.	13.9	601
52	Neratinibâ€‰+â€‰capecitabine sustains health-related quality of life in patients with HER2-positive metastatic breast cancer andâ€‰â‰¥â€‰2 prior HER2-directed regimens. Breast Cancer Research and Treatment, 2021, 188, 449-458.	1.1	2
53	Carbon-Based Nanomaterials: Promising Antiviral Agents to Combat COVID-19 in the Microbial-Resistant Era. ACS Nano, 2021, 15, 8069-8086.	7.3	134
54	Outcomes After Sentinel Lymph Node Biopsy and Radiotherapy in Older Women With Early-Stage, Estrogen Receptorâ€“Positive Breast Cancer. JAMA Network Open, 2021, 4, e216322.	2.8	15

#	Article	IF	Citations
55	Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.. Journal of Clinical Oncology, 2021, 39, 11036-11036.	0.8	0
56	MAF Amplification and Adjuvant Clodronate Outcomes in Early-Stage Breast Cancer in NSABP B-34 and Potential Impact on Clinical Practice. JNCI Cancer Spectrum, 2021, 5, pkab054.	1.4	7
57	Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.. Journal of Clinical Oncology, 2021, 39, 536-536.	0.8	2
58	Efficacy of enobosarm, a selective androgen receptor (AR) targeting agent, correlates with the degree of AR positivity in advanced AR+/estrogen receptor (ER)+ breast cancer in an international phase 2 clinical study.. Journal of Clinical Oncology, 2021, 39, 1020-1020.	0.8	27
59	A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. Annals of Oncology, 2021, 32, 652-660.	0.6	56
60	Real-world starting dose and outcomes of palbociclib plus an aromatase inhibitor for metastatic breast cancer.. Journal of Clinical Oncology, 2021, 39, e13021-e13021.	0.8	0
61	Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.. Journal of Clinical Oncology, 2021, 39, 502-502.	0.8	10
62	Phase I Study of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (ETCTN-9844). Clinical Cancer Research, 2021, 27, 5828-5837.	3.2	18
63	A unique view of SARS-CoV-2 through the lens of ORF8 protein. Computers in Biology and Medicine, 2021, 133, 104380.	3.9	48
64	Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial. Oncologist, 2021, 26, e1327-e1338.	1.9	31
65	Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2. International Journal of Biological Macromolecules, 2021, 181, 801-809.	3.6	36
66	Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3. Oncologist, 2021, 26, e1339-e1346.	1.9	16
67	Aromatase Inhibitor-Associated Musculoskeletal Syndrome: Understanding Mechanisms and Management. Frontiers in Endocrinology, 2021, 12, 713700.	1.5	27
68	COVID-19 Vaccines and Thrombosisâ€"Roadblock or Dead-End Street?. Biomolecules, 2021, 11, 1020.	1.8	28
69	Abstract CT260: The FLEX real-world data platform explores new gene expression profiles and investigator initiated protocols in early stage breast cancer. , 2021, , .		1
70	SARS-CoV-2 Research Using Human Pluripotent Stem Cells and Organoids. Stem Cells Translational Medicine, 2021, 10, 1491-1499.	1.6	16
71	Ovarian function suppression as a potential mechanism of chemotherapy. EBioMedicine, 2021, 70, 103489.	2.7	1
72	Real-World Tumor Response of Palbociclib Plus Letrozole Versus Letrozole for Metastatic Breast Cancer in US Clinical Practice. Targeted Oncology, 2021, 16, 601-611.	1.7	16

#	Article	IF	Citations
73	A plain language summary of the ASCENTÂstudy: Sacituzumab Govitecan for metastatic triple-negative breast cancer. Future Oncology, 2021, 17, 3911-3924.	1.1	9
74	The mechanism behind flaring/triggering of autoimmunity disorders associated with COVID-19. Autoimmunity Reviews, 2021, 20, 102909.	2.5	7
75	Implications derived from S-protein variants of SARS-CoV-2 from six continents. International Journal of Biological Macromolecules, 2021, 191, 934-955.	3.6	10
76	Dysregulation of the mevalonate pathway during SARSâ€CoVâ€2 infection: An in silico study. Journal of Medical Virology, 2021, 93, 2396-2405.	2.5	12
77	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. JAMA Oncology, 2020, 6, 367.	3.4	100
78	De Novo Versus Recurrent HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from the SystHERs Registry. Oncologist, 2020, 25, e214-e222.	1.9	39
79	Cost-effectiveness of denosumab for the prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Journal of Medical Economics, 2020, 23, 37-47.	1.0	19
80	Bisphosphonate Choice as Adjuvant Therapy for Breast Cancer: Does it Matter?. Journal of the National Cancer Institute, 2020, 112, 659-660.	3.0	5
81	Adjuvant bisphosphonate therapy in earlyâ€stage breast cancerâ€”Treating the soil to kill the seed. Breast Journal, 2020, 26, 65-68.	0.4	4
82	Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With â‰¥ 2 HER2-Directed Regimens: Phase III NALA Trial. Journal of Clinical Oncology, 2020, 38, 3138-3149.	0.8	355
83	Leveraging Bayesian networks and information theory to learn risk factors for breast cancer metastasis. BMC Bioinformatics, 2020, 21, 298.	1.2	4
84	The Evolving Landscape of HER2-Directed Breast Cancer Therapy. Current Treatment Options in Oncology, 2020, 21, 82.	1.3	17
85	The Importance of Research on the Origin of SARS-CoV-2. Viruses, 2020, 12, 1203.	1.5	27
86	TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes. Journal of Clinical Oncology, 2020, 38, 4274-4282.	0.8	276
87	Outcome of Everolimus-Based Therapy in Hormone-Receptor-Positive Metastatic Breast Cancer Patients After Progression on Palbociclib. Breast Cancer: Basic and Clinical Research, 2020, 14, 117822342094486.	0.6	20
88	Possible Transmission Flow of SARS-CoV-2 Based on ACE2 Features. Molecules, 2020, 25, 5906.	1.7	33
89	DC/Lâ€SIGNs of hope in the COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 1396-1398.	2.5	39
90	Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial. Annals of Oncology, 2020, 31, 1223-1230.	0.6	69

#	Article	IF	Citations
91	Ratcheting down the virulence of SARSâ€CoVâ€2 in the COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 2379-2380.	2.5	7
92	Baseline Characteristics, Treatment Patterns, and Outcomes in Patients with HER2-Positive Metastatic Breast Cancer by Hormone Receptor Status from SystHERs. Clinical Cancer Research, 2020, 26, 1105-1113.	3.2	19
93	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 519-530.	5.1	441
94	The healthcare value of the Magee Decision Algorithmâ„¢: use of Magee Equationsâ„¢ and mitosis score to safely forgo molecular testing in breast cancer. Modern Pathology, 2020, 33, 1563-1570.	2.9	27
95	Boning up: amino-bisphophonates as immunostimulants and endosomal disruptors of dendritic cell in SARS-CoV-2 infection. Journal of Translational Medicine, 2020, 18, 261.	1.8	32
96	Patient treatment and outcome after breast cancer orbital and periorbital metastases: a comprehensive case series including analysis of lobular versus ductal tumor histology. Breast Cancer Research, 2020, 22, 70.	2.2	15
97	Neratinib: the emergence of a new player in the management of HER2+ breast cancer brain metastasis. Future Oncology, 2020, 16, 247-254.	1.1	15
98	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors. Clinical Cancer Research, 2020, 26, 2546-2555.	3.2	33
99	The Association of Modifiable Breast Cancer Risk Factors and Somatic Genomic Alterations in Breast Tumors: The Cancer Genome Atlas Network. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 599-605.	1.1	7
100	Capivasertib inhibits a key pathway in metastatic breast cancer. Lancet Oncology, The, 2020, 21, 318-319.	5.1	2
101	Hyperglycemia, hydroxychloroquine, and the COVIDâ€19 pandemic. Journal of Medical Virology, 2020, 92, 770-775.	2.5	149
102	Distinct viral clades of SARSâ€CoVâ€2: Implications for modeling of viral spread. Journal of Medical Virology, 2020, 92, 1386-1390.	2.5	128
103	Abstract GS4-01: Ten-year results from NRG Oncology/NSABP B-42: A randomized, double-blinded, placebo-controlled clinical trial of extended adjuvant endocrine therapy with letrozole (L) in postmenopausal women with hormone-receptor+ breast cancer (BC) who have completed previous adjuvant therapy with an aromatase inhibitor (AI). Cancer Research, 2020, 80, GS4-01-GS4-01.	0.4	12
104	Abstract OT2-04-05: Pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease: Translational Breast Cancer Research Consortium (TBCRC) 44 trial. , 2020, , .		1
105	Abstract P1-19-02: Overall survival for first-line palbociclib plus letrozole vs letrozole alone for HR+/HER2- metastatic breast cancer patients in US real-world clinical practice. , 2020, , .		13
106	Abstract P1-19-08: Neratinib + trastuzumab + fulvestrant for HER2-mutant, hormone receptor-positive, metastatic breast cancer: Updated results from the phase 2 SUMMIT â€˜basketâ€™ trial. , 2020, , .		3
107	Abstract P2-20-01: Impact of neratinib on development and progression of central nervous system (CNS) metastases in patients with HER2-positive metastatic breast cancer (MBC): Findings from the NALA, NEfERT-T, and TBCRC 022 trials. Cancer Research, 2020, 80, P2-20-01-P2-20-01.	0.4	6
108	Abstract P5-04-28: Targeting TIGIT and PD-1 in triple negative breast cancer. , 2020, , .		4

#	Article	IF	Citations
109	TBCRC 048: A phase II study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in DNA damage response (DDR) pathway genes (Olaparib Expanded).. Journal of Clinical Oncology, 2020, 38, 1002-1002.	0.8	35
110	Safety and efficacy of single-agent adjuvant trastuzumab in older women with early-stage breast cancer.. Journal of Clinical Oncology, 2020, 38, 528-528.	0.8	4
111	Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS1102-TPS1102.	0.8	7
112	Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Reviews in Cardiovascular Medicine, 2020, 21, 517.	0.5	56
113	Loco-Regional Treatment for Intact Primary Tumor in Patient with De Novo Metastatic Breast Cancer; Comments and Concerns of ECOG-ACRIN 2108 Trial. The Journal of Breast Health, 2020, 16, 158-159.	0.4	8
114	Abstract OT2-02-05: A randomized trial of abemaciclib in combination with fulvestrant compared to chemotherapy in women with HR+, HER2- advanced breast cancer with visceral metastases. , 2020, , .		0
115	Ixabepilone efficacy and tolerability in metastatic breast cancer (MBC) patients in a real-world setting.. Journal of Clinical Oncology, 2020, 38, e13067-e13067.	0.8	1
116	Assisting decision making on the use of carboplatin for metastatic breast cancer.. Journal of Clinical Oncology, 2020, 38, e13008-e13008.	0.8	0
117	Adding precision to 2018 ASCO/CAP HER2 testing guidelines in breast cancer with genomic profiling.. Journal of Clinical Oncology, 2020, 38, 3570-3570.	0.8	3
118	The FLEX real-world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer.. Journal of Clinical Oncology, 2020, 38, TPS7088-TPS7088.	0.8	2
119	Abstract P1-17-12: The influence of social demographics on genomic sequencing in metastatic breast cancer. , 2020, , .		0
120	Abstract P2-21-02: Implementation of a breast cancer post-mortem tissue donation program. , 2020, , .		0
121	Abstract P5-08-07: Tobacco use, alcohol consumption, and breast cancer somatic genomic alterations. , 2020, , .		0
122	Abstract OT3-17-02: The FLEX real world data platform explores new gene expression profiles and investigator-initiated protocols in early stage breast cancer. , 2020, , .		0
123	Abstract P5-04-06: Reprogramming the suppressive tumor microenvironment of breast cancer. , 2020, , .		1
124	Abstract OT2-01-02: TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer. , 2020, , .		0
125	Abstract P1-19-26: Characteristics of MBC patients receiving first line treatments in the US real-world setting in the era of CDK4/6 inhibitors. , 2020, , .		1
126	Transcriptome Characterization of Matched Primary Breast and Brain Metastatic Tumors to Detect Novel Actionable Targets. Journal of the National Cancer Institute, 2019, 111, 388-398.	3.0	81

#	Article	IF	Citations
127	Artificial intelligence-directed prognostication of breast cancer. EBioMedicine, 2019, 46, 6-7.	2.7	2
128	A prospective decision-impact study incorporating Breast Cancer Index into extended endocrine therapy decision-making. Breast Cancer Management, 2019, 8, BMT22.	0.2	8
129	A Predictor of Pathological Complete Response to Neoadjuvant Chemotherapy Stratifies Triple Negative Breast Cancer Patients with High Risk of Recurrence. Scientific Reports, 2019, 9, 14863.	1.6	25
130	Peripheral neuropathy (PN), thrombocytopenia (TCP) and central nervous system (CNS) recurrence: An update of the phase III KATHERINE trial of post-neoadjuvant trastuzumab emtansine (T-DM1) or trastuzumab (H) in patients (pts) with residual invasive HER2-positive breast cancer (BC). Annals of Oncology, 2019, 30, v854-v855.	0.6	8
131	CDK4/6 inhibitors: taking the place of chemotherapy?. Lancet Oncology, The, 2019, 20, 1329-1330.	5.1	4
132	Extended adjuvant therapy for earlyâ€stage breast cancer: Are there markers for its use?. Breast Journal, 2019, 25, 7-8.	0.4	0
133	Metaplastic breast carcinoma: a clinical-pathologic study of 97 cases with subset analysis of response to neoadjuvant chemotherapy. Modern Pathology, 2019, 32, 807-816.	2.9	57
134	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. New England Journal of Medicine, 2019, 380, 2395-2405.	13.9	349
135	Treatment Patterns and Outcomes Associated With Palbociclib Plus Letrozole for Postmenopausal Women With HR+/HER2â^' Advanced Breast Cancer Enrolled in an Expanded Access Program. Clinical Breast Cancer, 2019, 19, 317-325.e4.	1.1	13
136	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases. Breast Cancer Research and Treatment, 2019, 176, 321-328.	1.1	17
137	A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis. PLoS ONE, 2019, 14, e0213292.	1.1	32
138	Targeted mutation detection in breast cancer using MammaSeqâ„¢. Breast Cancer Research, 2019, 21, 22.	2.2	28
139	Features Associated With Long-Term Survival in Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2019, 19, 304-310.	1.1	13
140	CACNG2 polymorphisms associate with chronic pain after mastectomy. Pain, 2019, 160, 561-568.	2.0	22
141	Central Nervous System Metastasis in Patients with HER2-Positive Metastatic Breast Cancer: Patient Characteristics, Treatment, and Survival from SystHERs. Clinical Cancer Research, 2019, 25, 2433-2441.	3.2	62
142	Frequent ESR1 and CDK Pathway Copy-Number Alterations in Metastatic Breast Cancer. Molecular Cancer Research, 2019, 17, 457-468.	1.5	29
143	Molecular mechanisms linking high body mass index to breast cancer etiology in post-menopausal breast tumor and tumor-adjacent tissues. Breast Cancer Research and Treatment, 2019, 173, 667-677.	1.1	19
144	Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 6 The, 2019, 20, 88-99.	5.1	108

#	Article	IF	Citations
145	Exploratory Study of Associations Between DNA Repair and Oxidative Stress Gene Polymorphisms and Cognitive Problems Reported by Postmenopausal Women With and Without Breast Cancer. Biological Research for Nursing, 2019, 21, 50-60.	1.0	4
146	Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use. Clinical Breast Cancer, 2019, 19, e7-e11.	1.1	4
147	Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containing BRCA1 and BRCA2 mutations. Cancer Research, 2019, 79, CT138-CT138.	0.4	10
148	Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with â‰¥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial.. Journal of Clinical Oncology, 2019, 37, 1002-1002.	0.8	71
149	Phase II COLET study: Atezolizumab (A) + cobimetinib (C) + paclitaxel (P)/nab-paclitaxel (nP) as first-line (1L) treatment (tx) for patients (pts) with locally advanced or metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2019, 37, 1013-1013.	0.8	26
150	A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2019, 37, 1057-1057.	0.8	27
151	Impact of clinical risk category on prognosis and prediction of chemotherapy benefit in early breast cancer (EBC) by age and the 21-gene recurrence score (RS) in TAILORx.. Journal of Clinical Oncology, 2019, 37, 503-503.	0.8	5
152	Clinical Trial in Progress: The FLEX Big Data Platform explores new gene expression profiles and investigator-initiated protocols in early-stage breast cancer.. Journal of Clinical Oncology, 2019, 37, TPS3155-TPS3155.	0.8	0
153	Abstract 929: Paired tumor and cfDNA in patients with HER2-mutant solid tumors treated with neratinib reveals convergence of multiple on-target resistance mechanisms: Results from the SUMMIT "Basket" Trial. , 2019, , .		1
154	Prognostic Significance of Modified Residual Disease in Breast and Nodes (mRDBN) Algorithm After Neoadjuvant Chemotherapy for Breast Cancer. American Journal of Clinical Pathology, 2018, 149, 332-343.	0.4	0
155	Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Annals of Oncology, 2018, 29, 872-880.	0.6	73
156	Estrogen Receptor-Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance. Oncologist, 2018, 23, 528-539.	1.9	102
157	Bisphosphonates in Early Breast Cancer. , 2018, , 769-772.e1.		0
158	Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. Journal of the National Cancer Institute, 2018, 110, .	3.0	85
159	Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Nodeâ€“Positive and High-Risk Lymph Nodeâ€“Negative Breast Cancer (E5103). Journal of Clinical Oncology, 2018, 36, 2621-2629.	0.8	52
160	Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. Journal of Clinical Oncology, 2018, 36, 1556-1563.	0.8	134
161	Statin drugs to reduce breast cancer recurrence and mortality. Breast Cancer Research, 2018, 20, 144.	2.2	130
162	Whole genome amplification of cell-free DNA enables detection of circulating tumor DNA mutations from fingerstick capillary blood. Scientific Reports, 2018, 8, 17313.	1.6	22

#	Article	IF	Citations
163	Trajectories of Cognitive Function and Associated Phenotypic and Genotypic Factors in Breast Cancer. Oncology Nursing Forum, 2018, 45, 308-326.	0.5	21
164	Expanded-Access Study of Palbociclib in Combination With Letrozole for Treatment of Postmenopausal Women With Hormone Receptorâ€“Positive, HER2-Negative Advanced Breast Cancer. Clinical Breast Cancer, 2018, 18, e1239-e1245.	1.1	17
165	Low Estrogen Receptor (ER)â€“Positive Breast Cancer and Neoadjuvant Systemic Chemotherapy. American Journal of Clinical Pathology, 2018, 150, 34-42.	0.4	47
166	Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2018, 379, 111-121.	13.9	1,558
167	nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Annals of Oncology, 2018, 29, 1763-1770.	0.6	94
168	Pathologist's healthâ€care value in the triage of Oncotype <scp>DX</scp>^{Â®} testing: a valueâ€based pathology study of tumour biology with outcomes. Histopathology, 2018, 73, 692-700.	1.6	3
169	Outcome of everolimus based therapy in hormone receptor positive metastatic breast cancer patients after progression on palbociclib combination.. Journal of Clinical Oncology, 2018, 36, 1064-1064.	0.8	14
170	Landscape of BRCA1 and BRCA2 germline, somatic, and reversion alterations detectable by cell-free DNA testing among patients with metastatic breast, ovarian, pancreatic, or prostate cancer.. Journal of Clinical Oncology, 2018, 36, 12097-12097.	0.8	1
171	Dissemination of breast cancer knowledge and expertise from NCI-CCC tumor boards with community oncologists.. Journal of Clinical Oncology, 2018, 36, e18575-e18575.	0.8	2
172	TAILORx: Phase III trial of chemoendocrine therapy versus endocrine therapy alone in hormone receptor-positive, HER2-negative, node-negative breast cancer and an intermediate prognosis 21-gene recurrence score.. Journal of Clinical Oncology, 2018, 36, LBA1-LBA1.	0.8	11
173	Use of cell-free DNA for management of breast and lung cancer by academic and community providers.. Journal of Clinical Oncology, 2018, 36, 12046-12046.	0.8	0
174	Features associated with long-term survival in metastatic breast cancer.. Journal of Clinical Oncology, 2018, 36, e13074-e13074.	0.8	0
175	Racial comparison of income, survival, co-morbidities and Trastuzumab therapy among Her 2+ women with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2018, 36, e18673-e18673.	0.8	0
176	A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies.. Journal of Clinical Oncology, 2018, 36, TPS1113-TPS1113.	0.8	0
177	Trajectories of self-reported cognitive function in postmenopausal women during adjuvant systemic therapy for breast cancer. Psycho-Oncology, 2017, 26, 44-52.	1.0	36
178	Characterizing Molecular Variants and Clinical Utilization of Next-generation Sequencing in Advanced Breast Cancer. Applied Immunohistochemistry and Molecular Morphology, 2017, 25, 392-398.	0.6	7
179	Associations between pathologic tumor features and preadjuvant therapy cognitive performance in women diagnosed with breast cancer. Cancer Medicine, 2017, 6, 339-348.	1.3	9
180	Less is more? De-intensification of therapy for early-stage HER2-positive breast cancer. Lancet Oncology, The, 2017, 18, 428-429.	5.1	1

#	Article	IF	Citations
181	Symptom incidence, distress, cancerâ€related distress, and adherence to chemotherapy among African American women with breast cancer. Cancer, 2017, 123, 2061-2069.	2.0	58
182	TITAN: phase III study of doxorubicin/cyclophosphamide followed by ixabepilone or paclitaxel in early-stage triple-negative breast cancer. Breast Cancer Research and Treatment, 2017, 164, 649-658.	1.1	19
183	Intrinsic Subtype Switching and Acquired ERBB2/HER2 Amplifications and Mutations in Breast Cancer Brain Metastases. JAMA Oncology, 2017, 3, 666.	3.4	135
184	Combination Epigenetic Therapy in Advanced Breast Cancer with 5-Azacitidine and Entinostat: A Phase II National Cancer Institute/Stand Up to Cancer Study. Clinical Cancer Research, 2017, 23, 2691-2701.	3.2	106
185	Higher Radiation Dose to Immune System is Correlated With Poorer Survival in Patients With Stage III Nonâ€“small Cell Lung Cancer: A Secondary Study of a Phase 3 Cooperative Group Trial (NRG Oncology) Tj ETQq1 1 0.784314 rgBT /Ov	0.4	45
186	Prevalence and determinants of end-of-life chemotherapy use in patients with metastatic breast cancer. Breast Journal, 2017, 23, 718-722.	0.4	16
187	Distinct Pattern of Metastases in Patients with Invasive Lobular Carcinoma of the Breast. Geburtshilfe Und Frauenheilkunde, 2017, 77, 660-666.	0.8	63
188	Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. Npj Breast Cancer, 2017, 3, 28.	2.3	13
189	Effect of gastroretentive gabapentin (Gralise) on postmastectomy pain syndrome: a proof-of-principle open-label study. Pain Reports, 2017, 2, e596.	1.4	2
190	The Double-Edged Sword: Controversies in Anthracycline-Based Chemotherapy for Breast Cancer. Current Breast Cancer Reports, 2017, 9, 210-216.	0.5	0
191	Long-term management of patients with hormone receptor-positive metastatic breast cancer: Concepts for sequential and combination endocrine-based therapies. Cancer Treatment Reviews, 2017, 59, 22-32.	3.4	38
192	Magee Equation 3 predicts pathologic response to neoadjuvant systemic chemotherapy in estrogen receptor positive, HER2 negative/equivocal breast tumors. Modern Pathology, 2017, 30, 1078-1085.	2.9	30
193	nab-Paclitaxel for the treatment of breast cancer: an update across treatment settings. Experimental Hematology and Oncology, 2017, 6, 7.	2.0	21
194	TACT2: improving treatment tolerability in early breast cancer. Lancet Oncology, The, 2017, 18, 843-845.	5.1	0
195	The Effect on Surgical Complications of Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer: NRG Oncology/NSABP Protocol B-40. Annals of Surgical Oncology, 2017, 24, 1853-1860.	0.7	8
196	Understanding the Needs of Patients with Metastatic Breast Cancer: Results of the Make Your Dialogue Count Survey. Breast Journal, 2017, 23, 17-25.	0.4	15
197	Alcohol consumption and breast tumor gene expression. Breast Cancer Research, 2017, 19, 108.	2.2	23
198	An exploratory study of host polymorphisms in genes that clinically characterize breast cancer tumors and pretreatment cognitive performance in breast cancer survivors. Breast Cancer: Targets and Therapy, 2017, Volume 9, 95-110.	1.0	15

#	Article	IF	Citations
199	Anthracyclines in Early Breast Cancer: The ABC Trialsâ€"USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology). Journal of Clinical Oncology, 2017, 35, 2647-2655.	0.8	223
200	Long-Term Follow-Up of Cardiac Function and Quality of Life for Patients in NSABP Protocol B-31/NRG Oncology: A Randomized Trial Comparing the Safety and Efficacy of Doxorubicin and Cyclophosphamide (AC) Followed by Paclitaxel With AC Followed by Paclitaxel and Trastuzumab in Patients With Node-Positive Breast Cancer With Tumors Overexpressing Human Epidermal Growth Factor Receptor 2. Journal of Clinical Oncology, 2017, 35, 3942-3948.	0.8	55
201	Exome-capture RNA sequencing of decade-old breast cancers and matched decalcified bone metastases. JCI Insight, 2017, 2, .	2.3	111
202	Number of tumor-infiltrating lymphocytes in breast cancer brain metastases compared to matched breast primaries.. Journal of Clinical Oncology, 2017, 35, 2049-2049.	0.8	4
203	Incidence of febrile neutropenia with use of docetaxel plus cyclophosphamide (TC) for breast cancer.. Journal of Clinical Oncology, 2017, 35, e12073-e12073.	0.8	2
204	Detection of ESR1 mutations in circulating cell-free DNA from patients with metastatic breast cancer treated with palbociclib and letrozole. Oncotarget, 2017, 8, 66901-66911.	0.8	40
205	Estradiol as a Targeted, Late-Line Therapy in Metastatic Breast Cancer with Estrogen Receptor Amplification. Cureus, 2017, 9, e1434.	0.2	12
206	Experience and impact of alopecia in patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry.. Journal of Clinical Oncology, 2017, 35, 239-239.	0.8	0
207	Health economic impact of breast cancer index (BCI) in patients with hormone responsive breast cancer (HRBC) considering extended adjuvant endocrine therapy (EET).. Journal of Clinical Oncology, 2017, 35, 25-25.	0.8	1
208	Examination and prognostic implications of the unique microenvironment of breast cancer brain metastases.. Journal of Clinical Oncology, 2017, 35, 2072-2072.	0.8	0
209	Abstract 421: Comprehensive genomic analysis of metastatic breast cancers revealsESR1fusions as a recurrent mechanism of endocrine therapy resistance. , 2017, , .		0
210	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study. Breast Cancer: Targets and Therapy, 2016, Volume 8, 231-239.	1.0	2
211	Beliefs in Chemotherapy and Knowledge of Cancer and Treatment Among African American Women With Newly Diagnosed Breast Cancer. Oncology Nursing Forum, 2016, 43, 180-189.	0.5	16
212	Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast Cancer. Clinical Cancer Research, 2016, 22, 5362-5369.	3.2	73
213	Risedronate may preserve bone microarchitecture in breast cancer survivors on aromatase inhibitors: A randomized, controlled clinical trial. Bone, 2016, 90, 123-126.	1.4	7
214	Is there room for bevacizumab in metastatic breast cancer?. Lancet Oncology, The, 2016, 17, 1175-1176.	5.1	2
215	Biomarkers for Early-Stage Breast Cancer: Clinical Utility for Extended Adjuvant Treatment Decisions. Journal of Clinical Oncology, 2016, 34, 3941-3942.	0.8	4
216	Ramucirumab With Eribulin Versus Eribulin in Locally Recurrent or Metastatic Breast Cancer Previously Treated With Anthracycline and Taxane Therapy: A Multicenter, Randomized, Phase II Study. Clinical Breast Cancer, 2016, 16, 471-479.e1.	1.1	29

#	Article	IF	Citations
217	Multiparametric Genomic Assays for Breast Cancer: Time for the Next Generation?. Clinical Cancer Research, 2016, 22, 4963-4965.	3.2	3
218	Exploration of communication gaps among women with metastatic breast cancer, caregivers and oncologists. Breast Cancer Management, 2016, 5, 151-160.	0.2	4
219	First-line cobimetinib (C) + paclitaxel (P) in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and tumoral immune cell infiltration data from the phase 2 COLET study. Annals of Oncology, 2016, 27, vi89.	0.6	0
220	Pathways Clinical Decision Support for Appropriate Use of Key Biomarkers. Journal of Oncology Practice, 2016, 12, e681-e687.	2.5	11
221	Polymorphisms in DNA repair and oxidative stress genes associated with pre-treatment cognitive function in breast cancer survivors: an exploratory study. SpringerPlus, 2016, 5, 422.	1.2	18
222	Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 849-856.	6.3	148
223	Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial. Lancet, The, 2016, 387, 857-865.	6.3	67
224	Sensitive Detection of Mono- and Polyclonal ESR1 Mutations in Primary Tumors, Metastatic Lesions, and Cell-Free DNA of Breast Cancer Patients. Clinical Cancer Research, 2016, 22, 1130-1137.	3.2	166
225	Interim joint analysis of the ABC (anthracyclines in early breast cancer) phase III trials (USOR 06-090,) Tj ETQq1 1 0.784314 rgBT /Ove anthracycline/taxane-based chemotherapy regimens (TaxAC) in women with high-risk, HER2-negative breast cancer.. Journal of Clinical Oncology, 2016, 34, 1000-1000.	0.8	12
226	Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. Journal of Clinical Oncology, 2016, 34, 1074-1074.	0.8	2
227	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: 5-year outcomes of NSABP protocol B-41.. Journal of Clinical Oncology, 2016, 34, 501-501.	0.8	19
228	HER2 equivocal breast cancer and neoadjuvant therapy: Is response similar to HER2-positive or HER2-negative tumors?. Journal of Clinical Oncology, 2016, 34, 612-612.	0.8	3
229	COLET (NCT02322814): A multistage, phase 2 study evaluating the safety and efficacy of cobimetinib (C) in combination with paclitaxel (P) as first-line treatment for patients (pts) with metastatic triple-negative breast cancer (TNBC).. Journal of Clinical Oncology, 2016, 34, TPS1100-TPS1100.	0.8	2
230	Predictors of trajectories of cognitive change in women with breast cancer.. Journal of Clinical Oncology, 2016, 34, 149-149.	0.8	0
231	Palbociclib's effect on estrogen receptor mutations in metastatic breast cancer.. Journal of Clinical Oncology, 2016, 34, 533-533.	0.8	2
232	Mitotic index to predict breast cancer recurrence after neoadjuvant systemic therapy.. Journal of Clinical Oncology, 2016, 34, e23265-e23265.	0.8	1
233	Low estrogen receptor (ER) positive breast cancer and neoadjuvant systemic therapy (NAT): Is response similar to ER+ or to ER- disease?. Journal of Clinical Oncology, 2016, 34, 580-580.	0.8	0
234	Utilization of Magee equation 3 in ER-positive, HER2-negative/equivocal tumors to determine pathologic response to neoadjuvant therapy.. Journal of Clinical Oncology, 2016, 34, 11594-11594.	0.8	0

#	Article	IF	Citations
235	Evaluation of the analytical performance of the Breast Cancer Index (BCI) assay.. Journal of Clinical Oncology, 2016, 34, 540-540.	0.8	1
236	Phase II/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials, 2015, 16, 575.	0.7	28
237	Bisphosphonates do not reduce breast cancer in postmenopausal women. Annals of Internal Medicine, 2015, 162, JC5.	2.0	0
238	Delaying Chemotherapy in the Treatment of Hormone Receptorâ€“Positive, Human Epidermal Growth Factor Receptor 2â€“Negative Advanced Breast Cancer. Clinical Medicine Insights: Oncology, 2015, 9, CMO.S31586.	0.6	15
239	Prognostic factors and survival of patients with brain metastasis from breast cancer who underwent craniotomy. Cancer Medicine, 2015, 4, 989-994.	1.3	61
240	Can Circulating Tumor Cells Predict Resistance in Metastatic Breast Cancer?. Clinical Cancer Research, 2015, 21, 2421-2423.	3.2	9
241	Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet, The, 2015, 386, 1353-1361.	6.3	581
242	Prevention of bone loss with risedronate in breast cancer survivors: a randomized, controlled clinical trial. Osteoporosis International, 2015, 26, 1857-1864.	1.3	36
243	Patterns of change in cognitive function with anastrozole therapy. Cancer, 2015, 121, 2627-2636.	2.0	79
244	Prospective Validation of a 21-Gene Expression Assay in Breast Cancer. New England Journal of Medicine, 2015, 373, 2005-2014.	13.9	1,146
245	Neoadjuvant plus adjuvant bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): secondary outcomes of a phase 3, randomised controlled trial. Lancet Oncology, The, 2015, 16, 1037-1048.	5.1	138
246	Developing in vitro models of human ductal carcinoma in situ from primary tissue explants. Breast Cancer Research and Treatment, 2015, 153, 311-321.	1.1	20
247	Bisphosphonates, bone, and breast cancer recurrence. Lancet, The, 2015, 386, 1319-1320.	6.3	13
248	Bisphosphonates in breast cancer. International Journal of Cancer, 2015, 137, 753-764.	2.3	36
249	The Effects of Reiki Therapy and Companionship on Quality of Life, Mood, and Symptom Distress During Chemotherapy. Journal of Evidence-Based Complementary & Alternative Medicine, 2015, 20, 20-27.	1.5	15
250	Abstract PD2-1: The effect on overall and disease-free survival (OS & DFS) by adding bevacizumab and/or antimetabolites to standard neoadjuvant chemotherapy: NSABP Protocol B-40. , 2015, , .		6
251	Abstract S3-02: NSABP B-36: A randomized phase III trial comparing six cycles of 5-fluorouracil (5-FU), epirubicin, and cyclophosphamide (FEC) to four cycles of adriamycin and cyclophosphamide (AC) in patients (pts) with node-negative breast cancer. , 2015, , .		9
252	Expression of high affinity folate receptor in breast cancer brain metastasis. Oncotarget, 2015, 6, 30327-30333.	0.8	12

#	Article	IF	Citations
253	Prognostic significance of transcription factors FOXA1 and GATA-3 in ductal carcinoma in situ in terms of recurrence and estrogen receptor status. Journal of Cancer Metastasis and Treatment, 2015, 1, 84.	0.5	4
254	Abstract OT2-2-01: tnAcity: A phase II/III trial ofnab-paclitaxel (nab-P) plus either gemcitabine (Gem) or carboplatin (Carbo) vs Gem/Carbo as first-line treatment for patients with triple-negative metastatic breast cancer (TNMBC). , 2015, , .		0
255	Abstract S1-03: Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene specifically in hormone-resistant recurrence. , 2015, , .		0
256	Abstract P6-01-15: Expression of high affinity folate receptor in breast cancer brain metastasis. , 2015, , .		0
257	Histopathological markers at craniotomy and outcome in breast cancer brain metastases.. Journal of Clinical Oncology, 2015, 33, 2027-2027.	0.8	0
258	Detection and functional analysis of estrogen receptor mutations (ESR1-mut) in patients with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2015, 33, 554-554.	0.8	0
259	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.. Journal of Clinical Oncology, 2015, 33, 533-533.	0.8	0
260	Weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) vs gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC) in a phase 2/3 trial (tnAcity).. Journal of Clinical Oncology, 2015, 33, TPS1106-TPS1106.	0.8	0
261	End-of-life chemotherapy use in metastatic breast cancer.. Journal of Clinical Oncology, 2015, 33, e20505-e20505.	0.8	0
262	Doctor-patient perceptions and discourse on side effects related to metastatic breast cancer (MBC) treatment: The Make Your Dialogue Count survey.. Journal of Clinical Oncology, 2015, 33, e20575-e20575.	0.8	0
263	Metastatic pattern of invasive lobular carcinoma.. Journal of Clinical Oncology, 2015, 33, e11561-e11561.	0.8	0
264	Is Body Mass Index a prognostic factor in early-stage breast cancer patients who subsequently developed metastatic disease?. Journal of Clinical Oncology, 2015, 33, e12639-e12639.	0.8	0
265	Emotional experiences of oncologists treating women with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2015, 33, 97-97.	0.8	0
266	Abstract B2-16: Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene in hormone-resistant progression. , 2015, , .		0
267	Abstract A1-07: Identification of base pair mutations and structural rearrangements acquired in breast cancer metastases including a novel hyperactive ESR1-DAB2 fusion gene in hormone-resistant progression. , 2015, , .		0
268	A New Method for Predicting Patient Survivorship Using Efficient Bayesian Network Learning. Cancer Informatics, 2014, 13, CIN.S13053.	0.9	13
269	Metastasis of Breast Carcinoma to the Maxillary Sinus. Breast Journal, 2014, 20, 318-319.	0.4	2
270	Managing Postmenopausal Women with Hormone Receptor-Positive Advanced Breast Cancer Who Progress on Endocrine Therapies with Inhibitors of the PI3K Pathway. Breast Journal, 2014, 20, 347-357.	0.4	3

#	Article	IF	Citations
271	Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptorâ€“positive, Node-positive Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2014, 37, 404-410.	0.6	22
272	Influence of Patient and Treatment Factors on Adherence to Adjuvant Endocrine Therapy in Breast Cancer. Oncology Nursing Forum, 2014, 41, 274-285.	0.5	105
273	Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER. British Journal of Cancer, 2014, 110, 2756-2764.	2.9	51
274	Utilizing Microtubule Dynamics Inhibitor Therapeutics in the Management of Patients With Metastatic Breast Cancer. Clinical Breast Cancer, 2014, 14, e111.	1.1	0
275	Length of chemotherapy and use of bevacizumab for breast cancer. Lancet Oncology, The, 2014, 15, 1285-1287.	5.1	0
276	Zoledronic acidâ€”more than just a bone drug. Nature Reviews Clinical Oncology, 2014, 11, 564-565.	12.5	6
277	Treatment patterns and clinical outcomes for patients with de novo versus recurrent HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2014, 145, 725-734.	1.1	67
278	The bone substudy of MA.27: does bone make a difference?. Lancet Oncology, The, 2014, 15, 375-377.	5.1	2
279	Current Approaches and Emerging Directions in HER2-resistant Breast Cancer. Breast Cancer: Basic and Clinical Research, 2014, 8, BCBCR.S9453.	0.6	21
280	Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103.. Journal of Clinical Oncology, 2014, 32, 500-500.	0.8	38
281	Comparison of test results and clinical outcomes of patients assessed with both MammaPrint and Oncotype DX with pathologic variables: An independent study.. Journal of Clinical Oncology, 2014, 32, 550-550.	0.8	7
282	Phase 2 study investigating the safety, efficacy, and surrogate biomarkers of response to 5-azacitidine (5-AZA) and entinostat in advanced breast cancer.. Journal of Clinical Oncology, 2014, 32, 569-569.	0.8	3
283	tnAcity: A phase II/III trial of weekly nab-paclitaxel (nab-P) plus gemcitabine (gem) or carboplatin (carbo) versus gem/carbo as first-line treatment for metastatic triple-negative breast cancer (mTNBC).. Journal of Clinical Oncology, 2014, 32, TPS1146-TPS1146.	0.8	2
284	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase 2, single-arm, multicenter study.. Journal of Clinical Oncology, 2014, 32, 139-139.	0.8	1
285	Persistent pain following breast cancer surgery: Why does it hurt more for some survivors than others?. Journal of Clinical Oncology, 2014, 32, e20634-e20634.	0.8	0
286	Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for HER2+ locally recurrent or metastatic breast cancer (MBC): Results from a phase II, single-arm, multicenter study.. Journal of Clinical Oncology, 2014, 32, 635-635.	0.8	1
287	Recurrence score and clinicopathologic characteristics of TAILORx participants by race and ethnicity.. Journal of Clinical Oncology, 2014, 32, 36-36.	0.8	1
288	Understanding potential communication gaps between oncologists and patients with advanced breast cancer: A survey of oncologists.. Journal of Clinical Oncology, 2014, 32, 124-124.	0.8	0

#	Article	IF	Citations
289	Effect of tumor subtype on overall survival in brain metastatic breast cancer patients treated with cranial irradiation.. Journal of Clinical Oncology, 2014, 32, 74-74.	0.8	0
290	The use of adjuvant bisphophonates in the treatment of early-stage breast cancer. Clinical Advances in Hematology and Oncology, 2014, 12, 749-56.	0.3	6
291	Precision Oncology in Breast Cancer: Better than Ever, or Less than Before?. Breast Journal, 2013, 19, 355-356.	0.4	7
292	Using Mice to Treat (Wo)men: Mining Genetic Changes in Patient Xenografts to Attack Breast Cancer. Cell Reports, 2013, 4, 1061-1062.	2.9	2
293	Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP) Tj ETQq1 1 0.784314 rgBT /Overlock	5.1	332
294	Persistent pain in postmastectomy patients: Comparison of psychophysical, medical, surgical, and psychosocial characteristics between patients with and without pain. Pain, 2013, 154, 660-668.	2.0	149
295	Long-term Treatment with Intravenous Bisphosphonates in Metastatic Breast Cancer: A Retrospective Study. Breast Journal, 2013, 19, n/a-n/a.	0.4	20
296	Definitive Results of a Phase III Adjuvant Trial Comparing Three Chemotherapy Regimens in Women With Operable, Node-Positive Breast Cancer: The NSABP B-38 Trial. Journal of Clinical Oncology, 2013, 31, 3197-3204.	0.8	129
297	Treatment of HER2-positive breast cancer: looking backwards briefly. Lancet Oncology, The, 2013, 14, 1250-1251.	5.1	4
298	How to Develop and Deliver Pathway-Based Care. Hematology/Oncology Clinics of North America, 2013, 27, 843-850.	0.9	3
299	Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2013, 141, 461-470.	1.1	38
300	Persistent Postmastectomy Pain in Breast Cancer Survivors: Analysis of Clinical, Demographic, and Psychosocial Factors. Journal of Pain, 2013, 14, 1185-1195.	0.7	171
301	Therapeutic approaches for HER2-positive brain metastases: Circumventing the bloodâ€“brain barrier. Cancer Treatment Reviews, 2013, 39, 261-269.	3.4	73
302	Breast cancer survivorship symptom management: current perspective and future development. Breast Cancer Management, 2013, 2, 71-81.	0.2	16
303	First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER. Oncologist, 2013, 18, 501-510.	1.9	63
304	Breast Cancer Index Identifies Early-Stage Estrogen Receptorâ€“Positive Breast Cancer Patients at Risk for Early- and Late-Distant Recurrence. Clinical Cancer Research, 2013, 19, 4196-4205.	3.2	184
305	Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis. Oncologist, 2013, 18, 353-361.	1.9	67
306	Does lifetime exposure to hormones predict pretreatment cognitive function in women before adjuvant therapy for breast cancer?. Menopause, 2013, 20, 905-913.	0.8	11

#	Article	IF	Citations
307	An Isoform of C/EBPÎ², LIP, Regulates Expression of the Chemokine Receptor CXCR4 and Modulates Breast Cancer Cell Migration*. Journal of Biological Chemistry, 2013, 288, 28656-28667.	1.6	27
308	Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Modern Pathology, 2013, 26, 658-664.	2.9	163
309	Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. Obstetrical and Gynecological Survey, 2013, 68, 201-202.	0.2	8
310	Abstract 4666: A phase 2 study investigating the safety, efficacy and surrogate biomarkers of response of 5-azacitidine (5-AZA) andentinostat (MS-275) in patients with triple-negative advanced breast cancer.. Cancer Research, 2013, 73, 4666-4666.	0.4	8
311	Initial results from the 21-gene breast cancer assay registry: A prospective observational study in patients (pts) with ER+, early-stage invasive breast cancer (EBC).. Journal of Clinical Oncology, 2013, 31, 565-565.	0.8	1
312	Efficacy and safety of first-line (1L) pertuzumab (P), trastuzumab (T), and docetaxel (D) in HER2-positive MBC (CLEOPATRA) in patients previously exposed to trastuzumab.. Journal of Clinical Oncology, 2013, 31, 600-600.	0.8	3
313	Prediction of early and late distant recurrence in early-stage breast cancer with Breast Cancer Index.. Journal of Clinical Oncology, 2013, 31, 594-594.	0.8	0
314	Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy.. Journal of Clinical Oncology, 2013, 31, e22017-e22017.	0.8	0
315	Prognostic factors and survival of patients with brain metastasis (BM) from breast cancer (BC) who underwent craniotomy.. Journal of Clinical Oncology, 2013, 31, 143-143.	0.8	0
316	Seven-Year Follow-Up Assessment of Cardiac Function in NSABP B-31, a Randomized Trial Comparing Doxorubicin and Cyclophosphamide Followed by Paclitaxel (ACP) With ACP Plus Trastuzumab As Adjuvant Therapy for Patients With Node-Positive, Human Epidermal Growth Factor Receptor 2â€“Positive Breast Cancer. Journal of Clinical Oncology, 2012, 30, 3792-3799.	0.8	446
317	Prognostic/Predictive Immunohistochemistry Assays for Estrogen Receptorâ€“Positive Breast Cancer: Back to the Future?. Journal of Clinical Oncology, 2012, 30, 4451-4453.	0.8	5
318	Connexin 47 Mutations Increase Risk for Secondary Lymphedema Following Breast Cancer Treatment. Clinical Cancer Research, 2012, 18, 2382-2390.	3.2	95
319	Reply to A. Kesikli et al. Journal of Clinical Oncology, 2012, 30, 461-462.	0.8	1
320	Comorbidity as a Mediator of Survival Disparity Between Younger and Older Women Diagnosed With Metastatic Breast Cancer. Hypertension, 2012, 59, 205-211.	1.3	22
321	Bone-Related Complications and Quality of Life in Advanced Breast Cancer: Results from a Randomized Phase III Trial of Denosumab versus Zoledronic Acid. Clinical Cancer Research, 2012, 18, 4841-4849.	3.2	124
322	Analysis of FcÎ³ Receptor IIIa and IIa Polymorphisms: Lack of Correlation with Outcome in Trastuzumab-Treated Breast Cancer Patients. Clinical Cancer Research, 2012, 18, 3478-3486.	3.2	106
323	Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast) Tj ETQq1 1 0.784314 rgBT /Ove Oncology, The, 2012, 13, 734-742.	5.1	168
324	Adjuvant treatment of HER2-positive breast cancer: winning efforts continue to improve HER2-positive patient outcome long-term. Breast Cancer Research, 2012, 14, 308.	2.2	2

#	Article	IF	Citations
325	Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?. Breast Cancer Research, 2012, 14, 213.	2.2	24
326	Treatment patterns and clinical outcomes in elderly patients with HER2-positive metastatic breast cancer from the registHER observational study. Breast Cancer Research and Treatment, 2012, 135, 875-883.	1.1	51
327	Adverse events risk associated with bevacizumab addition to breast cancer chemotherapy: a meta-analysis. Annals of Oncology, 2012, 23, 1130-1137.	0.6	60
328	Comprehensive molecular portraits of human breast tumours. Nature, 2012, 490, 61-70.	13.7	10,282
329	Bevacizumab Added to Neoadjuvant Chemotherapy for Breast Cancer. New England Journal of Medicine, 2012, 366, 310-320.	13.9	416
330	Cancer treatment-induced bone loss in premenopausal women: A need for therapeutic intervention?. Cancer Treatment Reviews, 2012, 38, 798-806.	3.4	78
331	Patient preferences for chemotherapies used in breast cancer. International Journal of Women's Health, 2012, 4, 279.	1.1	26
332	Decreased risk of breast cancer associated with oral bisphosphonate therapy. Breast Cancer: Targets and Therapy, 2012, 4, 75.	1.0	5
333	Second-line bevacizumab-containing therapy in patients with triple-negative breast cancer: subgroup analysis of the RIBBON-2 trial. Breast Cancer Research and Treatment, 2012, 133, 1067-1075.	1.1	103
334	Final 5â€yyear results of Zâ€FAST trial. Cancer, 2012, 118, 1192-1201.	2.0	161
335	Factors associated with mortality after breast cancer metastasis. Cancer Causes and Control, 2012, 23, 103-112.	0.8	104
336	NSABP B-38: Definitive analysis of a randomized adjuvant trial comparing dose-dense (DD) ACâ†'paclitaxel (P) plus gemcitabine (G) with DD ACâ†'P and with docetaxel, doxorubicin, and cyclophosphamide (TAC) in women with operable, node-positive breast cancer.. Journal of Clinical Oncology, 2012, 30, LBA1000-LBA1000.	0.8	8
337	Evaluation of lapatinib as a component of neoadjuvant therapy for HER2+ operable breast cancer: NSABP protocol B-41.. Journal of Clinical Oncology, 2012, 30, LBA506-LBA506.	0.8	21
338	Final overall survival (OS) and safety analyses of RIBBON-2, a randomized phase III trial of bevacizumab (BEV) versus placebo (PL) combined with second-line chemotherapy (CT) for HER2-negative BEV-naive metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, 100-100.	0.8	5
339	Long-term survivor (LTS) characteristics in HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, 133-133.	0.8	1
340	Driving Evidence-Based Standardization of Care within a Framework of Personalized Medicine. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , e62-e65.	1.8	1
341	Racial disparities in treatment patterns and clinical outcomes in patients (pts) with HER2+ metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2012, 30, 1526-1526.	0.8	0
342	RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2â€"Negative, Locally Recurrent or Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 1252-1260.	0.8	932

#	Article	IF	Citations
343	Prognostic utility of the breast cancer index and comparison to Adjuvant! Online in a clinical case series of early breast cancer. Breast Cancer Research, 2011, 13, R98.	2.2	49
344	Adjuvant bisphosphonates for early-stage breast cancer. Lancet Oncology, The, 2011, 12, 610-611.	5.1	3
345	New antiresorptive agents in metastatic breast cancer: an advance or more of the same?. Community Oncology, 2011, 8, 61-62.	0.2	0
346	Ixabepilone in advanced breast cancer: clinical, treatment, and cost-related studies. Community Oncology, 2011, 8, 73-80.	0.2	0
347	Understanding the estrogen receptor signaling pathway: focus on current endocrine agents for breast cancer in postmenopausal women. Community Oncology, 2011, 8, 343-352.	0.2	3
348	The beginning of small molecule therapy for endocrine-resistant metastatic breast cancer?. Community Oncology, 2011, 8, 498-500.	0.2	0
349	Direct interaction between NHERF1 and Frizzled regulates Î²-catenin signaling. Oncogene, 2011, 30, 32-42.	2.6	48
350	Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial. Clinical Breast Cancer, 2011, 11, 82-92.	1.1	113
351	A Randomized Phase II Study of Paclitaxel and Bevacizumab With and Without Gemcitabine as First-Line Treatment for Metastatic Breast Cancer. Clinical Breast Cancer, 2011, 11, 211-220.	1.1	29
352	The impact of an aromatase inhibitor on body composition and gonadal hormone levels in women with breast cancer. Breast Cancer Research and Treatment, 2011, 125, 441-446.	1.1	45
353	The effect of delays in treatment for breast cancer metastasis on survival. Breast Cancer Research and Treatment, 2011, 130, 953-964.	1.1	39
354	Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. Journal of Neurosurgery, 2011, 114, 792-800.	0.9	108
355	Management of aromatase inhibitor-associated bone loss in postmenopausal women with breast cancer: practical guidance for prevention and treatment. Annals of Oncology, 2011, 22, 2546-2555.	0.6	156
356	A Case of Late-Onset Gemcitabine Lung Toxicity. Clinical Medicine Insights: Oncology, 2011, 5, CMO.S6643.	0.6	10
357	The Attitudes, Communication, Treatment, and Support Intervention to Reduce Breast Cancer Treatment Disparity. Oncology Nursing Forum, 2011, 38, 85-89.	0.5	26
358	Phase III trial of gemcitabine plus docetaxel versus capecitabine plus docetaxel with planned crossover to the alternate single agent in metastatic breast cancer. Annals of Oncology, 2011, 22, 1094-1101.	0.6	27
359	Central Nervous System Metastases in Patients with HER2-Positive Metastatic Breast Cancer: Incidence, Treatment, and Survival in Patients from registHER. Clinical Cancer Research, 2011, 17, 4834-4843.	3.2	318
360	Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Modern Pathology, 2011, 24, 367-374.	2.9	50

#	Article	IF	Citations
361	RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2â€“Negative Metastatic Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4286-4293.	0.8	379
362	Trastuzumab-Based Therapy for Patients With HER2-Positive Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 186-195.	0.6	64
363	The Evolving Role of Bone-Conserving Therapy in Patients With Breast Cancer. Seminars in Oncology, 2010, 37, S12-S19.	0.8	5
364	Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy. Cancer, 2010, 116, 1431-1439.	2.0	129
365	Localization of CD44 and CD90 positive cells to the invasive front of breast tumors. Cytometry Part B - Clinical Cytometry, 2010, 78B, 287-301.	0.7	59
366	Metastatic Breast Cancer or Multiple Myeloma? Camouflage by Lytic Lesions. Journal of Oncology, 2010, 2010, 1-3.	0.6	7
367	CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer. Journal of the National Cancer Institute, 2010, 102, 1496-1512.	3.0	148
368	Transcatheter Arterial Chemoembolization Is a Feasible Palliative Locoregional Therapy for Breast Cancer Liver Metastases. International Journal of Surgical Oncology, 2010, 2010, 1-8.	0.3	18
369	Understanding and Optimizing Bone Health in Breast Cancer. Current Medical Research and Opinion, 2010, 26, 3-20.	0.9	25
370	Phase II Trial of Weekly Nanoparticle Albumin-Bound Paclitaxel With Carboplatin and Trastuzumab as First-line Therapy for Women With HER2-Overexpressing Metastatic Breast Cancer. Clinical Breast Cancer, 2010, 10, 281-287.	1.1	86
371	Metastasis and bone loss: Advancing treatment and prevention. Cancer Treatment Reviews, 2010, 36, 615-620.	3.4	121
372	Randomized Controlled Trial of the Breast Cancer Recovery Program for Women With Breast Cancerâ€“Related Lymphedema. American Journal of Occupational Therapy, 2010, 64, 59-72.	0.1	46
373	Challenges of illness in metastatic breast cancer: A low-income African American perspective. Palliative and Supportive Care, 2009, 7, 143-152.	0.6	15
374	Small Beginnings: Do They Matter? The Importance of Lymphovascular Invasion in Early Breast Cancer. Journal of the National Cancer Institute, 2009, 101, 698-699.	3.0	1
375	Zoledronic Acid Effectively Prevents Aromatase Inhibitorâ€“Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results. Clinical Breast Cancer, 2009, 9, 77-85.	1.1	194
376	Adjuvant endocrine therapy for premenopausal women with breast cancer. Breast, 2009, 18, S122-S130.	0.9	35
377	A phase II trial of trastuzumab in combination with low-dose interleukin-2 (IL-2) in patients (PTS) with metastatic breast cancer (MBC) who have previously failed trastuzumab. Breast Cancer Research and Treatment, 2009, 117, 83-89.	1.1	45
378	Multicenter Phase II Study of Lapatinib in Patients with Brain Metastases from HER2-Positive Breast Cancer. Clinical Cancer Research, 2009, 15, 1452-1459.	3.2	592

#	Article	IF	Citations
379	The Unique Perspective of Illness Among Women With Metastatic Breast Cancer According to Race and Income. Journal of Hospice and Palliative Nursing, 2009, 11, 27-38.	0.5	8
380	Bone health issues in women with early-stage breast cancer receiving aromatase inhibitors. Current Oncology Reports, 2008, 10, 18-26.	1.8	9
381	Histopathologic variables predict Oncotype DXâ„¢ Recurrence Score. Modern Pathology, 2008, 21, 1255-1261.	2.9	202
382	Clinical importance of HER2 immunohistologic heterogeneous expression in core-needle biopsies vs resection specimens for equivocal (immunohistochemical score 2+) cases. Modern Pathology, 2008, 21, 363-368.	2.9	45
383	RiBBON 1 and RiBBON 2: Phase III Trials of Bevacizumab with Standard Chemotherapy for Metastatic Breast Cancer. Clinical Breast Cancer, 2008, 8, 370-373.	1.1	33
384	Myelotoxicity of samarium Sm 153 lexidronam in patients receiving prior treatment with chemotherapy or radiotherapy. Annals of Oncology, 2008, 19, 1639-1643.	0.6	15
385	Pleomorphic Lobular Carcinoma In Situ (PLCIS) on Breast Core Needle Biopsies. American Journal of Surgical Pathology, 2008, 32, 1721-1726.	2.1	102
386	Double-Blind, Randomized Placebo Controlled Trial of Fulvestrant Compared With Exemestane After Prior Nonsteroidal Aromatase Inhibitor Therapy in Postmenopausal Women With Hormone Receptorâ€“Positive, Advanced Breast Cancer: Results From EFECT. Journal of Clinical Oncology, 2008, 26, 1664-1670.	0.8	460
387	Integrated Analysis of Zoledronic Acid for Prevention of Aromatase Inhibitorâ€“Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole. Oncologist, 2008, 13, 503-514.	1.9	165
388	Risedronate Prevents Bone Loss in Breast Cancer Survivors: A 2-Year, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of Clinical Oncology, 2008, 26, 2644-2652.	0.8	82
389	Practical guidance for the management of aromatase inhibitor-associated bone loss. Annals of Oncology, 2008, 19, 1407-1416.	0.6	208
390	Cancer Treatmentâ€Induced Bone Loss: Pathophysiology and Clinical Perspectives. Oncologist, 2008, 13, 187-195.	1.9	67
391	Zoledronic acid for cancer therapy-induced and postmenopausal bone loss. Expert Opinion on Pharmacotherapy, 2008, 9, 1013-1028.	0.9	5
392	Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. Biologics: Targets and Therapy, 2008, 2, 505.	3.0	14
393	What do perceived cognitive problems reflect?. The Journal of Supportive Oncology, 2008, 6, 238-42.	2.3	32
394	Prevention of Bone Loss in Survivors of Breast Cancer: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 131-136.	1.8	45
395	Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2â€“Overexpressing Locally Advanced Breast Cancer. Journal of Clinical Oncology, 2007, 25, 1232-1238.	0.8	78
396	Memory impairments with adjuvant anastrozole versus tamoxifen in women with early-stage breast cancer. Menopause, 2007, 14, 995-998.	0.8	133

#	Article	IF	Citations
397	Zoledronic Acid Inhibits Adjuvant Letrozoleâ€“Induced Bone Loss in Postmenopausal Women With Early Breast Cancer. Journal of Clinical Oncology, 2007, 25, 829-836.	0.8	307
398	Managing Bone Loss in Women with Early-Stage Breast Cancer Receiving Aromatase Inhibitors. Clinical Breast Cancer, 2007, 8, S22-S34.	1.1	11
399	Inhibin-B Levels in Healthy Young Adult Men and Prepubertal Boys: Is Obesity the Cause for the Contemporary Decline in Sperm Count Because of Fewer Sertoli Cells?. Journal of Andrology, 2006, 27, 560-564.	2.0	94
400	Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology, 2006, 15, 422-430.	1.0	277
401	Management of Cancer-Treatmentâ€“Induced Bone Loss in Postmenopausal Women Undergoing Adjuvant Breast Cancer Therapy: A Z-FAST Update. Seminars in Oncology, 2006, 33, 13-17.	0.8	52
402	Phase II Study of Neoadjuvant Docetaxel/Vinorelbine Followed by Surgery and Adjuvant Doxorubicin/Cyclophosphamide in Women with Stage II/III Breast Cancer. Clinical Breast Cancer, 2006, 6, 511-517.	1.1	13
403	Phase II trial of high-dose, intermittent calcitriol (1,25 dihydroxyvitamin D3) and dexamethasone in androgen-independent prostate cancer. Cancer, 2006, 106, 2136-2142.	2.0	100
404	Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers. Journal of Immunology, 2006, 177, 2717-2727.	0.4	16
405	Phyllodes Tumor: A Clinicopathologic and Immunohistochemical Study of 30 Cases. Archives of Pathology and Laboratory Medicine, 2006, 130, 1516-1521.	1.2	70
406	Single-fraction radiosurgery for the treatment of spinal breast metastases. Cancer, 2005, 104, 2244-2254.	2.0	139
407	Long-term survivors after gamma knife radiosurgery for brain metastases. Cancer, 2005, 104, 2784-2791.	2.0	111
408	Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Metastatic and Locally Advanced Breast Cancer. Journal of Clinical Oncology, 2005, 23, 2726-2734.	0.8	215
409	Phase I Pharmacokinetic-Pharmacodynamic Study of 17-(Allylamino)-17-Demethoxygeldanamycin (17AAG,) Tj ETQq1 1 0.784314 rgBT /O Clinical Cancer Research, 2005, 11, 3385-3391.	3.2	192
410	The Nurse as Principal Investigator in a Pharmaceutically Sponsored Drug Trial: Considerations and Challenges. Oncology Nursing Forum, 2005, 32, 293-299.	0.5	6
411	Hormone Receptor Status Does Not Affect the Clinical Benefit of Trastuzumab Therapy for Patients with Metastatic Breast Cancer. Clinical Breast Cancer, 2005, 6, 247-252.	1.1	47
412	Low Overexpression of HER-2/Neu in Advanced Colorectal Cancer Limits the Usefulness of Trastuzumab (HerceptinÂ®) and Irinotecan as Therapy. A Phase II Trial. Cancer Investigation, 2004, 22, 858-865.	0.6	130
413	The decision to prematurely terminate a trial of R-HuEPO due to thrombotic events. Journal of Pain and Symptom Management, 2004, 27, 185-190.	0.6	94
414	Evaluation of the OncoTCap(Oncology Thinking Cap) Simulation in Teaching Medical Students About Clinical Trials: Some Successes and Some Surprises. Journal of Cancer Education, 2004, 19, 149-155.	0.6	2

#	Article	IF	Citations
415	Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology, 2003, 62, 99-104.	0.5	23
416	Testosterone, sex hormone-binding globulin, and body composition in young adult African American and Caucasian men. Metabolism: Clinical and Experimental, 2001, 50, 1242-1247.	1.5	133
417	Oncology Thinking Cap: Scaffolded Use of a Simulation to Learn Clinical Trial Design. Teaching and Learning in Medicine, 2001, 13, 183-191.	1.3	15
418	Molecular Anatomy of an Intracranial Aneurysm. Stroke, 2001, 32, 1036-1042.	1.0	132
419	Health care professionals' grief: a model based on occupational style and coping. Psycho-Oncology, 2001, 10, 187-198.	1.0	59
420	Comprehensive transcript analysis in small quantities of mRNA by SAGE-Lite. Nucleic Acids Research, 1999, 27, 39e-39.	6.5	94
421	Phase II Trial of the Antiestrogen Toremifene for Androgen-Independent Prostate Cancer. Prostate Journal, 1999, 1, 185-189.	0.2	1
422	The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 3320-3323.	3.3	754
423	Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology, 1997, 49, 913-920.	0.5	81
424	A mutation of the glucocorticoid receptor in primary cortisol resistance.. Journal of Clinical Investigation, 1993, 91, 1918-1925.	3.9	189
425	Real-World Effectiveness of Palbociclib Plus Letrozole vs Letrozole Alone for Metastatic Breast Cancer With Lung or Liver Metastases: Flatiron Database Analysis. Frontiers in Oncology, 0, 12, .	1.3	5